Loading organizations...
Key people at Curasight.
Based in Copenhagen, Denmark, Curasight is a clinical-stage biotechnology company that develops uPAR theranostics technology, combining uTRACE for precise PET imaging diagnostics and uTREAT for targeted radioligand radiation therapy in cancer care. The firm focuses on oncology solutions for prostate, glioblastoma, neuroendocrine, and head and neck cancers, advancing its pipeline through clinical trials. Curasight completed its initial public offering on the Spotlight Stock Market in 2020, raising DKK 97 million to fund its research and development programs. The company operates a strategic partnership with Curium that includes up to USD 70 million in potential milestone payments for its uTRACE technology. In 2025, the enterprise expanded its financial backing by adding Curium and Pentwater as strategic shareholders to support ongoing clinical evaluations. Curasight was founded in 2013 by Professor Andreas Kjaer alongside three other researchers.
Key people at Curasight.
Curasight is a clinical-stage Danish biotech company headquartered in Copenhagen, focused on advancing cancer diagnosis and treatment through its proprietary uPAR Theranostics platform.[1][2][3] The platform combines uTRACE®, a precise PET imaging diagnostic for tumor characterization, with uTREAT®, a targeted radionuclide therapy that minimizes healthy tissue irradiation, addressing aggressive cancers like brain, prostate, and others.[1][2][4] Serving cancer patients and partnering with pharmaceutical firms, Curasight solves key challenges in oncology by enabling more accurate staging and gentler, efficient therapies; it has completed multiple Phase II trials with over 400 patients scanned and is publicly listed on Sweden's Spotlight Stock Exchange since 2020, with recent funding including a DKK 47 million rights issue and over EUR 20 million raised to date.[3][4][5][6]
Founded in 2013 in Copenhagen, Denmark, Curasight emerged from over 10 years of academic research at Rigshospitalet (Copenhagen University Hospital) led by Professor Andreas Kjær, the company's CSO and co-founder, who pioneered the uPAR biomarker technology.[1][2][4] The idea stemmed from understanding uPAR's role in cancer aggression, evolving from diagnostic imaging (uTRACE®) into a full theranostics platform with therapy (uTREAT®).[2][4] Early traction included investigator-initiated Phase II trials across prostate, head & neck, neuroendocrine tumors, and more, building a robust clinical foundation; pivotal moments feature its 2020 IPO on Spotlight Stock Market and recent first-patient dosing in a Phase 1 uTREAT® brain cancer trial.[3][4][5]
Curasight rides the explosive growth in radiopharmaceuticals and theranostics, a market projected to reach $35 billion by 2031, fueled by aging populations, rising cancer incidence, and nuclear medicine adoption.[3][4] Timing is ideal amid trends like precision oncology (e.g., PSMA successes inspiring uPAR expansion) and demand for biomarkers beyond FDG-PET limitations in aggressive tumors.[2][5] Favorable forces include regulatory tailwinds for targeted therapies and partnerships like Curium's, which de-risk manufacturing/commercialization; Curasight influences the ecosystem by validating uPAR across cancers, potentially enabling pharma combos and setting standards for "intelligent imaging" to guide treatments, filling gaps in brain/prostate cancer management.[1][4][10]
Curasight's near-term catalysts include Phase III uTRACE® protocols (planned post-2022), uTREAT® Phase 1 data readouts, Curium milestones, and funding for commercialization/partnerships, positioning it for regulatory approvals in EU/US.[3][5][6][10] Trends like AI-enhanced imaging, expanded radiopharma pipelines, and global nuclear medicine infrastructure will amplify its trajectory, with brain/prostate focus unlocking blockbuster potential in underserved areas. Its influence could evolve from pioneer to market leader via pharma alliances, ultimately delivering game-changing cancer care as envisioned in its mission—transforming millions of lives through uPAR precision.[1][3][7]
